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RESEARCH
The food supply, including poultry products, may trans-
mit antimicrobial drug–resistant Escherichia coli to humans. 
To assess this hypothesis, 931 geographically and tempo-
rally matched E. coli isolates from human volunteers (hos-
pital inpatients and healthy vegetarians) and commercial 
poultry products (conventionally raised or raised without 
antimicrobial drugs) were tested by PCR for phylogenetic 
group (A, B1, B2, D) and 60 virulence genes associated 
with extraintestinal pathogenic E. coli. Isolates resistant to 
trimethoprim-sulfamethoxazole, quinolones, and extended-
spectrum cephalosporins (n = 331) were compared with 
drug-susceptible isolates (n = 600) stratiﬁ   ed by source. 
Phylogenetic and virulence markers of drug-susceptible 
human isolates differed considerably from those of human 
and poultry isolates. In contrast, drug-resistant human iso-
lates were similar to poultry isolates, and drug-susceptible 
and drug-resistant poultry isolates were largely indistin-
guishable. Many drug-resistant human fecal E. coli isolates 
may originate from poultry, whereas drug-resistant poultry-
source E. coli isolates likely originate from susceptible poul-
try-source precursors.
A
cquired resistance to ﬁ   rst-line antimicrobial agents 
increasingly complicates the management of extraint-
estinal infections due to Escherichia coli, which are a ma-
jor source of illness, death, and increased healthcare costs 
(1–4). One suspected source of drug-resistant E. coli in hu-
mans is use of antimicrobial drugs in agriculture. This use 
presumably selects for drug-resistant E. coli, which may be 
transmitted to humans through the food supply (5–7). Sup-
porting this hypothesis is the high prevalence of antimicro-
bial drug–resistant E. coli in retail meat products, especially 
poultry (8–11), and the similar molecular characteristics of 
ﬂ  uoroquinolone-resistant E. coli from chicken carcasses and 
from colonized and infected persons in Barcelona, Spain, in 
contrast to the marked differences between drug-susceptible 
and drug-resistant source isolates from humans (12).
To further assess the poultry-human connection, we 
used molecular typing to characterize drug  -resistant and 
drug-susceptible E. coli isolates from feces of human vol-
unteers or newly hospitalized patients in Minnesota and 
Wisconsin and from poultry products sold or processed in 
the same region. Resistance phenotypes of interest include 
trimethoprim-sulfamethoxazole (TMP-SMZ), quinolones/
ﬂ  uoroquinolones, and extended-spectrum cephalosporins. 
These agents are used for treatment of human E. coli infec-
tions. These drugs (or congeners) are also used in poultry 
production (e.g., each year in the United States an estimat-
ed 1.6 billion broiler eggs or chicks receive ceftiofur [13]); 
E. coli isolates resistant to these drugs are found in poul-
try. We examined, according to phylogenetic group distri-
bution and virulence gene proﬁ  le, whether drug-resistant 
human isolates more closely resemble susceptible human 
isolates, which is consistent with acquisition of resistance 
within humans, or instead resemble poultry isolates, which 
is consistent with foodborne transmission of poultry-source 
organisms to humans. We also examined whether poultry-
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source resistant and susceptible isolates are similar, which 
is consistent with emergence of resistance on farms under 
selection from agricultural use of antimicrobial drugs.
Methods
Participants and Bacterial Strains
Human fecal samples were collected from 622 adults 
newly admitted to local hospitals in 4 rural communities in 
Minnesota (Willmar) or Wisconsin (Eau Claire, La Crosse, 
and Marshﬁ  eld) and from 100 healthy self-identiﬁ  ed veg-
etarians in these and nearby communities (14). Hospi-
tal patients were recruited from June 2002 through May 
2003, vegetarians during the ﬁ  rst 6 months of 2004. Fecal 
samples were collected by study personnel by using rectal 
swabs (hospital patients) or by the participants (vegetar-
ians). To prevent isolation of hospital-acquired ﬂ  ora, inpa-
tients samples were collected within 36 hours of hospital 
admission. Guidelines of the authors’ institutions regard-
ing use of human subjects were followed in this study. The 
relevant institutional review boards reviewed and approved 
the protocol. All participants provided informed consent.
A total of 180 retail poultry products (155 chicken and 
25 turkey) were sampled (14). Conventional brands were 
purchased systematically from all food markets in the 4 
primary study communities from May 2002 through May 
2003, with 40 retail items obtained per community (total 
160 items). These represented at least 18 plants in 11 states. 
Twenty samples with labels indicating that the poultry were 
raised naturally or without antibiotics were purchased in or 
near the study communities in August 2004. Additionally, 
40 freshly slaughtered chicken carcasses from local farm-
ers who raised chickens naturally or without antibiotics 
were obtained during plant inspections by the Minnesota 
Department of Agriculture from September 2003 through 
August 2004. The latter 2 groups of chickens, designated 
“no antibiotics,” were conﬁ  rmed to have been raised with-
out antibiotics, based on the product label or by contacting 
the manufacturer or distributor.
Sample Processing
Human fecal samples were suspended and poultry 
samples and carcasses were massaged in nutrient broth, 
which was then incubated overnight at 37°C and stored as 
aliquots at –80°C in glycerol (14). Portions of these fro-
zen stocks were transferred to vancomycin-supplemented 
(20 mg/L) Luria-Bertani broth. After overnight incubation, 
these broths were plated directly onto modiﬁ  ed Mueller-
Hinton (MMH) agar (Amyes medium) (10) with and with-
out ciproﬂ  oxacin (4 mg/L) and (separately) nalidixic acid 
(32 mg/L), and were then incubated overnight. Samples of 
these Luria-Bertani broths containing vancomycin were 
placed in MMH broths supplemented individually with 
TMP-SMZ (4 mg/L TMP plus 76 mg/mL SMZ), cefoxitin 
(10 mg/L and 32 mg/L), and ceftazidime (10 mg/L and 32 
mg/L). After overnight incubation, these broths were plated 
onto MMH agar plates supplemented with the correspond-
ing agent (same concentrations) for overnight incubation. 
Colonies resembling E. coli were identiﬁ  ed by using the 
API-20E System (bioMérieux, Marcy-l’Etoile, France).
Susceptibility Testing
At least 1 E. coli colony was randomly selected from 
each MMH agar plate and tested for disk susceptibility to 
24 antimicrobial agents by using Clinical Laboratory Stan-
dards Institute (CLSI)–recommended methods, interpretive 
criteria, and reference strains (15). For isolates resistant to 
TMP-SMZ, nalidixic acid, or ciproﬂ  oxacin, the MIC was 
determined by Etest (AB-Biodisk, Sona, Sweden) accord-
ing to the manufacturer’s directions. Isolates from cefoxi-
tin- and ceftazidime-supplemented plates underwent broth 
dilution MIC determinations with cefotaxime and ceftazi-
dime regardless of disk test results. Isolates were classiﬁ  ed 
as resistant to TMP-SMZ if the TMP MIC was >4 mg/L 
and the SMZ MIC was >76 mg/L, to quinolones if the na-
lidixic acid MIC was >32 mg/L, to ﬂ  uoroquinolones if the 
ciproﬂ  oxacin MIC was >4 mg/L, and to extended-spectrum 
cephalosporins if the MIC to either cefotaxime or ceftazi-
dime was >16 mg/L. The latter threshold corresponds with 
intermediate susceptibility per CLSI criteria and includes 
isolates with potentially clinically relevant reduced suscep-
tibility. Because of the small number of isolates within each 
resistance phenotype, isolates were classiﬁ  ed as resistant if 
they met any of these resistance criteria. Isolates that did 
not meet any of these resistance criteria were classiﬁ  ed as 
susceptible, even though they may have had reduced sus-
ceptibility to other drug classes.
From each sample, 1 colony of each resistance phe-
notype (TMP-SMZ, quinolones, ﬂ  uoroquinolones, extend-
ed-spectrum cephalosporins) and 1 susceptible isolate, as 
available, were selected. If multiple isolates from a given 
sample exhibited similar disk diffusion susceptibility pro-
ﬁ  les, genomic proﬁ  les as generated by using random ampli-
ﬁ  ed polymorphic DNA (RAPD) analysis were compared 
in the same gel (12). One representative of each unique 
RAPD genotype (as determined by visual inspection) was 
arbitrarily selected for further analysis.
Phylogenetic Analysis and Virulence Genotyping
All isolates were categorized as to major E. coli phylo-
genetic group (A, B1, B2, or D) by a multiplex PCR-based 
assay (16) (Table 1). Genes encoding proven or putative 
virulence factors of extraintestinal pathogenic E. coli (Ex-
PEC) were detected in a sequential fashion. All isolates 
were screened for 5 ExPEC-deﬁ  ning virulence genes and 
hlyD (hemolysin). Isolates were operationally deﬁ  ned as RESEARCH
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ExPEC if ≥2 of the following were present: papA and/or 
papC (P ﬁ  mbriae structural subunit and assembly), sfa/
focDE (S and F1C ﬁ  mbriae), afa/draBC (Dr binding ad-
hesins), iutA (aerobactin system), and kpsM II (group 2 
capsule) (8). All ExPEC isolates were then tested for 60 
ExPEC-associated virulence genes and alleles thereof. 
Testing was conducted by using 2 independently prepared 
lysates of each isolate and established PCR-based methods 
(12,17). Isolates from various source groups (e.g., hospital 
volunteers, conventionally raised poultry) were tested in 
parallel to avoid cohort effects. The virulence score was the 
number of virulence genes detected adjusted for multiple 
detection of the pap, sfa/foc, and kps operons (12).
Statistical Methods
The unit of analysis was the individual isolate. Com-
parisons of proportions were tested by using Fisher ex-
act test (2-tailed). Comparisons of virulence scores were 
tested by using Mann-Whitney U test (2-tailed exact 
probability). Principal coordinates analysis (PCA), also 
known as metric multidimensional scaling, is a multivari-
ate statistical technique used to provide a simpler, low-
dimensional graphic summary of the similarity between 
multiple samples (e.g., isolates) across multiple loci (18). 
New axes for plotting the isolates are derived from a data 
matrix of estimated dissimilarities between isolates. The 
ﬁ  rst 2 principal coordinates, which account for the most 
variance, are used to plot the data. The distances between 
points in the plot represent isolate similarity. The dimen-
sions represented by the (statistically uncorrelated) axes 
have no intrinsic meaning, i.e., they have no units. Using 
GenAlEx6 (19), we applied PCA to the screening dataset 
(all isolates) and the extended virulence proﬁ  le dataset 
(ExPEC isolates) as a way to collapse the multiple vari-
ables for simpliﬁ  ed among-group comparisons. For each 
PCA, results for each isolate from the ﬁ  rst 2 PCA axes 
were used in multiple analysis of variance (MANOVA) 
to test for among-group differences. These values also 
were plotted to spatially represent the degree of separa-
tion or overlap of isolates on the 2-axis plane. For the 
ExPEC isolates, pairwise similarity relationships accord-
ing to extended virulence proﬁ  les and phylogenetic group 
were used to construct a dendrogram according to the 
unweighted pair group method with arithmetic averages 
(20). The criterion for statistical signiﬁ  cance throughout 
was p≤0.01 to account for multiple comparisons.
Results
Isolation of Drug-Resistant and 
Drug-Susceptible E. coli
Selective processing of 942 human fecal and poultry 
samples yielded 931 unique E. coli isolates, which consti-
tuted the study population. Of the 931 isolates, 530 (57%) 
were from human volunteers and 401 (43%) from poultry 
products. Of the human isolates, 456 (86%) were from hos-
pital patients and 74 (14%) from vegetarians. Of the poul-
try isolates, 289 (72%) were from conventionally raised 
retail poultry and 112 (28%) from poultry raised without 
antibiotics. The median number of unique E. coli isolates 
Table 1. Bacterial traits by source and antimicrobial drug resistance in 931 Escherichia coli isolates from human feces and poultry 
products, Minnesota and Wisconsin, 2002–2004* 
Prevalence, no. (%)  p value‡ 
Trait† 
Total  
(n = 931) 
Human, susceptible 
(n = 460) 
Human, resistant 
(n = 70) 
Poultry  
(n = 401)  HS vs. HR 
HS vs. all 
poultry 
HR vs. all 
poultry 
Group A  252 (27)  96 (21)  23 (33)  133 (33)  ≤0.001
Group B1  186 (20)  79 (17)  11 (16)  96 (24) 
Group B2  234 (25)  178 (39)  13 (19)  43 (11)  ≤0.001 ≤0.001
Group D  259 (28)  107 (23)  23 (33)  129 (32)  ≤0.01
papA 124 (13)  98 (21)  6 (9)  20 (5)  ≤0.001
papC 163 (18)  100 (22)  10 (14)  53 (13)  ≤0.001
sfa/focDE 69 (7)  65 (14)  2 (3)  2 (0.5)  ≤0.01 ≤0.001
afa/draBC 19 (2)  14 (3)  5 (7)  0 (0)  ≤0.001 ≤0.001
iutA 361 (39)  93 (20)  32 (46)  236 (59)  ≤0.001§ ≤0.001§
kpsM II  288 (31)  195 (42)  23 (33)  70 (17)  ≤0.001 ≤0.01
hlyD 71 (8)  64 (14)  2 (3)  4 (1)  ≤0.01 ≤0.001
ExPEC 249 (27)  147 (32)  20 (29)  82 (20)  ≤0.001
*Data are for the total population. Susceptible, susceptible to trimethoprim-sulfamethoxazole, nalidixic acid (quinolones), and ceftriaxone or ceftazidime 
(extended-spectrum cephalosporins), regardless of other possible drug resistance; resistant, resistant to 1 of the following: trimethoprim-
sulfamethoxazole, nalidixic acid (quinolones), and ceftriaxone or ceftazidime (extended-spectrum cephalosporins).  
†Groups A, B1, B2, and D, major E. coli phylogenetic groups; papA and papC, P fimbriae structural subunit and assembly; sfa/focDE, S and F1C 
fimbriae; afa/draBC, Dr binding adhesins; iutA, aerobactin system; kpsM II, group 2 capsule; hlyD,  -hemolysin; ExPEC, extraintestinal pathogenic E. coli
defined by presence of ≥2 of papA and/or papC (counted as 1), sfa/focDE, afa/draBC, iutA, and kpsM II. 
‡By Fisher exact test. Values are shown only where p≤0.01. HS, susceptible isolates from humans; HR, resistant isolates from humans. Because drug-
resistant and drug-susceptible poultry isolates showed only 1 significant difference (for iutA), they were combined into an all-poultry group. 
§Negative association. Drug-Resistant E. coli from Humans and Poultry
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per sample was 1 for human fecal samples and 2 for poultry 
(range 1–4 for both).
Overall, 331 isolates (70 human, 261 poultry) were 
classiﬁ  ed as resistant on the basis of reduced susceptibility 
to TMP-SMZ, quinolones/ﬂ  uoroquinolones, and extended-
spectrum cephalosporins. The remaining 600 isolates (460 
human, 140 poultry) were susceptible to all these drug 
classes and were classiﬁ  ed as susceptible (regardless of 
other possible drug resistance). The resistant isolates were 
distributed by resistance phenotype as follows: TMP-SMZ, 
154 (47 human, 107 poultry); quinolones, 115 (26 human, 
89 poultry); and extended-spectrum cephalosporins, 114 
(14 human, 100 poultry). The 7 ﬂ  uoroquinolone-resistant 
isolates (5 human, 2 poultry) were analyzed within the qui-
nolone-resistant group.
Phylogenetic Distribution and Prevalence 
of ExPEC-deﬁ  ning Markers
The initial screening showed the 931 isolates to be 
fairly evenly distributed among the 4 major E. coli phylo-
genetic groups (20%–28% per group). However, they had 
various prevalences (2%–39% each) of the screening Ex-
PEC virulence genes (Table 1). Overall, 27% of the isolates 
qualiﬁ  ed as ExPEC by having ≥2 of the 5 ExPEC-deﬁ  ning 
markers (Table 1).
For enhanced resolution of similarities and differences, 
the 243 available ExPEC isolates underwent extended viru-
lence genotyping for 60 ExPEC-associated virulence genes. 
All but 6 of these traits were detected in ≥1 isolate each, with 
prevalences ranging from 0.4% to 98% (Table 2).
Prevalence Comparisons
Phylogenetic group distribution and virulence gene 
prevalence differed considerably according to source (hu-
man versus poultry) and resistance status. This ﬁ  nding is 
shown in Table 1 for all 931 isolates (screening virulence 
genes only) and in Table 2 for the 243 ExPEC isolates 
(extended virulence proﬁ  les). Drug-resistant and drug-sus-
ceptible human isolates were separately compared with the 
combined group of all poultry isolates (i.e., all susceptible 
and resistant). We analyzed poultry isolates as a single 
group because the distribution of traits was similar in drug-
resistant and susceptible poultry isolates; i.e., only 1 trait 
(iutA) was signiﬁ  cantly associated with resistance among 
poultry isolates.
Consistent differences in phylogenetic and virulence 
gene distribution were evident between groups (Tables 1, 2). 
First, drug-susceptible human isolates differed considerably 
from drug-resistant human isolates. Second, drug-suscep-
tible human isolates differed from poultry isolates. Third, 
although human drug-resistant isolates and poultry isolates 
exhibited some differences, these were considerably fewer 
and less extreme than those between drug-susceptible hu-
man isolates and poultry isolates. Similar results were ob-
tained in subgroup analyses when isolates from hospital pa-
tient fecal samples were compared separately with isolates 
from conventionally raised poultry or when isolates from 
fecal samples from vegetarians were compared separately 
with isolates from poultry raised without antibiotics.
PCA
PCA was used to concurrently analyze multiple bac-
terial characteristics. The ﬁ   rst PCA was conducted for 
the total population (n = 931) with the 7 screening viru-
lence genes plus phylogenetic group. According to a 2 × 
2 (source × resistance status) MANOVA of the ﬁ  rst 2 axes 
of the PCA (which accounted for 65% of total variance), 
all 3 independent variables considered (source, resistance 
status, and interaction term) showed a p value ≤0.001. Ac-
cordingly, pairwise comparisons were made between in-
dividual source-resistance groups by 1-factor MANOVA. 
Susceptible human isolates differed (p<0.001) from each 
of the other 3 groups, whereas the other 3 groups differed 
marginally from each other. The individual axes supported 
this conclusion. These axes showed more extreme differ-
ences between drug-susceptible human isolates and each of 
the other 3 groups (p<0.001 for 5 of 6 comparisons) than 
among the other groups (p>0.01 for 4 of 6 comparisons).
Next, PCA was conducted for the 243 available Ex-
PEC isolates based on all 60 virulence genes plus phyloge-
netic group. According to an initial 2 × 2 MANOVA of the 
results from the ﬁ  rst 2 PCA axes (which accounted for 57% 
of total variance), all 3 independent variables (source, resis-
tance status, and interaction term) showed a p value <0.001. 
Accordingly, pairwise comparisons were made between in-
dividual source-resistance groups by 1-factor MANOVA. 
Susceptible human isolates differed (p<0.001) from each 
of the other 3 groups, whereas the other 3 groups did not 
differ signiﬁ  cantly from each another. In a plot of the (axis 
1–axis 2) plane, drug-susceptible poultry isolates, drug-re-
sistant poultry isolates, and drug-resistant human isolates 
overlapped and were conﬁ  ned largely to the left half of the 
grid (negative values on axis 1). In contrast, drug-suscep-
tible human isolates, although overlapping somewhat with 
these groups, were concentrated principally within the right 
half of the grid (positive values on axis 1) (Figure 1).
Aggregate Virulence Scores
The various source and resistance groups were also 
compared for aggregate virulence scores (ExPEC isolates 
only). According to virulence score distribution, drug-sus-
ceptible human isolates (higher scores) segregated widely 
from the other 3 subgroups (lower scores), which were 
largely superimposed on each another (Figure 2). Because 
drug-resistant and drug-susceptible poultry isolates had 
similar virulence scores, they were combined for statistical RESEARCH
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analysis. Drug-susceptible human isolates had the highest 
scores (median 13.0, range 4.25–20.0). Drug-resistant hu-
man and poultry isolates had signiﬁ  cantly lower scores that 
did not differ between humans and poultry (median 9.0, 
range 6.0–15.25, and median 8.75, range 3.75–15.0, re-
spectively; vs. drug-susceptible human isolates, p<0.001). 
Similar results were obtained when isolates from hospital 
patient fecal samples were compared separately with the 
conventionally raised poultry isolates or when isolates 
from vegetarian fecal samples were compared separately 
with isolates from poultry raised without antibiotics (data 
not shown).
Table 2. Bacterial traits by source and antimicrobial drug resistance in 243 extraintestinal pathogenic Escherichia coli (ExPEC) isolates 
from human feces and poultry products, Minnesota and Wisconsin, 2002–2004* 
Prevalence, no. (%)  p value¶ 
Trait†‡§
Total 
(n = 243) 
Human, susceptible 
(n = 144) 
Human, resistant 
(n = 20) 
Poultry 
(n = 79)  HS vs. HR 
HS vs. all 
poultry 
HR vs. all 
poultry 
Group A  20 (8)  5 (3)  5 (25)  10 (13)  ≤0.01#
Group B1  7 (3)  0 0 7 (9)  ≤0.001# ≤0.001#
Group B2  154 (63)  125 (87)  6 (30)  23 (29)  ≤0.001
Group D  62 (26)  14 (10)  9 (45)  39 (49)  ≤0.001#
papA 117 (48)  97 (67)  7 (35)  13 (16)  ≤0.01 ≤0.001
F10 allele  38 (16)  32 (10)  5 (25)  1 (1)  ≤0.001 ≤0.001
F16 allele  12 (5)  5 (3)  5 (25)  2 (3)  ≤0.01# ≤0.01
F48 allele  21 (9)  21 (15)  0 0 ≤0.001
papG III  44 (18)  44 (31)  0 0 ≤0.01 ≤0.001
sfa/focDE 62 (26)  61 (42)  1 (5)  0 ≤0.001 ≤0.001
sfaS 35 (14)  33 (23)  1 (5)  1 (1)  ≤0.001
focG 13 (5)  12 (8)  1 (5)  0 ≤0.01
afa/draBC 15 (6)  11 (8)  4 (20)  0 ≤0.01 ≤0.001
iha 52 (22)  38 (26)  16 (80)  0 ≤0.001# ≤0.001 ≤0.001
hra 108 (44)  67 (47)  2 (10)  39 (49)  ≤0.001 ≤0.01#
cnf1 54 (22)  51 (35)  2 (10)  1 (1)  ≤0.001
hlyD 67 (28)  67 (28)  2 (10)  2 (3)  ≤0.01 ≤0.001
hlyF 73 (30)  28 (19)  1 (5)  44 (57)  ≤0.001# ≤0.001#
sat 61 (25)  46 (32)  15 (75)  0 (0)  ≤0.001# ≤0.001# ≤0.001#
pic 34 (14)  30 (21)  0 4 (5)  ≤0.01
vat 131 (54)  113 (78)  3 (15)  15 (19)  ≤0.001 ≤0.001
astA 48 (20)  7 (5)  1 (5)  40 (51)  ≤0.001# ≤0.001#
iutA 162 (67)  67 (47)  18 (90)  77 (97)  ≤0.001#
iroN 118 (49)  78 (54)  3 (15)  37 (47)  ≤0.001 ≤0.01#
fyuA 199 (82)  138 (96)  17 (85)  44 (56)  ≤0.001
kpsM II  215 (89)  137 (95)  16 (80)  62 (78)  ≤0.001
K5 kpsM 35 (14)  28 (19)  4 (20)  3 (4)  ≤0.001
iss 69 (28)  23 (16)  2 (10)  44 (56)  ≤0.001# ≤0.001#
usp 144 (59)  127 (88)  6 (30)  11 (14)  ≤0.001 ≤0.001
H7 fliC 52 (21)  52 (36)  0 0 ≤0.001 ≤0.001
ompT 184 (76)  131 (91)  9 (50)  40 (51)  ≤0.01 ≤0.001
malX 152 (63)  134 (93)  7 (35)  1 (14)  ≤0.001 ≤0.001
*Susceptible, susceptible to trimethoprim-sulfamethoxazole, nalidixic acid (quinolones), and ceftriaxone or ceftazidime (extended-spectrum 
cephalosporins), regardless of other possible drug resistance; resistant, resistant to >1 of the following: trimethoprim-sulfamethoxazole, nalidixic acid 
(quinolones), and ceftriaxone or ceftazidime (extended-spectrum cephalosporins). 
†Traits are shown that showed p≤0.01 for ≥1 comparison each. Groups A, B1, B2, and D, major E. coli phylogenetic groups; papA, P fimbriae structural 
subunit with variants F10, F16, and F48; papG III, variant P adhesin; sfa/focDE, S and F1C fimbriae; sfaS, S fimbriae; focG, F1C fimbriae; afa/draBC, Dr 
binding adhesins; iha, adhesin-siderophore receptor; hra, pathogenicity island marker; cnf1, cytotoxic necrotizing factor 1; hlyD,  -hemolysin; hlyF, variant 
hemolysin; sat, secreted autotransporter toxin; pic, autotransporter protease; vat, vacuolating autotransporter; astA, enteroaggregative E. coli toxin; iutA,
aerobactin system; iroN, siderophore receptor; fyuA, yersiniabactin receptor; kpsM II, group 2 capsule; K5 kpsM, kpsM II variant; iss, increased serum 
survival; usp, uropathogenic-specific protein; H7 fliC, flagellar variant; ompT, outer membrane protease; malX, pathogenicity island marker.  
‡Traits that did not show p<0.01 but were detected in ≥1 isolate each include the F7–2, F8, F9, F11, F12, F12, F14, and F15 papA alleles, papC (P 
fimbriae assembly), papEF (P fimbriae tip pilins), papG alleles I and II (both internal and flanking sequences), afaE8 (variant Dr binding adhesin), gafD (G 
fimbriae), F17 fimbriae, fimH (type 1 fimbriae), clpG (adhesin), cdtB (cytolethal distending toxin B), ireA (siderophore receptor), kpsM III (group 3 capsule), 
K1 and K2 kpsM II variants, cvaC (microcin V), ibeA (invasion of brain endothelium), and rfc (O4 lipopolysaccharide biosynthesis). 
§Traits not detected in any isolate include F7–1 and F536 papA alleles and K15 kpsM II variant. 
¶By Fisher exact test. Values are shown only where p≤0.01. HS, susceptible isolates from humans; HR, drug-resistant isolates from humans. Because 
drug-resistant and drug-susceptible poultry isolates showed no significant differences, they were combined into an all-poultry group.
#Negative association. Drug-Resistant E. coli from Humans and Poultry
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Dendrogram of Extended Virulence Proﬁ  les 
and Phylogenetic Group
Phylogenetic group and extended virulence proﬁ  les 
among the 243 available ExPEC isolates also were used to 
construct a similarity dendrogram. The dendrogram showed 
3 major clusters, each of which contained 2 prominent sub-
clusters (Figure 3). Isolates were distributed by cluster and 
subcluster according to source and resistance group; that is, 
drug-susceptible human isolates accounted for almost all 
of subclusters 1a, 1b, and 2a. In contrast, drug-resistant hu-
man isolates were conﬁ  ned largely to subcluster 3a. Poultry 
isolates, whether resistant or susceptible, were conﬁ  ned al-
most entirely to subclusters 2b, 3a, and 3b. Thus, compared 
with drug-susceptible human isolates, drug-resistant hu-
man isolates were signiﬁ  cantly more likely to occur within 
a subcluster, or major cluster, that also contained poultry 
isolates (p<0.001 for each comparison).
The possible effects of nonindependence among mul-
tiple isolates acquired from the same sample were assessed 
by limiting the analysis to a single isolate per sample, keep-
ing a drug-susceptible isolate (if available) and randomly 
selecting among multiple drug-resistant isolates where re-
quired. This resulted in reduced sample sizes of 681 (to-
tal population) and 226 (ExPEC population). The analysis 
results closely mirrored the pattern of signiﬁ  cant ﬁ  ndings 
obtained in the full samples.
Discussion
In this study, we analyzed the phylogenetic distribu-
tion and virulence genotypes of drug-susceptible and drug-
resistant E. coli isolates from human volunteers and poultry 
products in Minnesota and Wisconsin. We found that drug-
resistant human isolates, although overlapping somewhat 
with drug-susceptible human isolates, were more similar 
overall to poultry isolates than to drug-susceptible human 
isolates. In contrast, drug-susceptible human isolates dif-
fered from poultry isolates. This relationship was observed 
consistently with diverse analytical approaches and various 
stratiﬁ  cations of the population. It suggests that many of 
the drug-resistant human isolates were more likely to have 
originated in poultry (or a similar nonhuman reservoir) and 
to have been acquired by humans when these isolates were 
already drug resistant, than to have emerged de novo in hu-
mans by conversion of drug-susceptible human isolates to 
drug-resistant isolates.
We also found that, regardless of analytical approach 
and population analyzed, resistant and susceptible poultry 
isolates were highly similar. This suggests that the resistant 
poultry isolates likely derived from antimicrobial drug–
Figure 1. Principal coordinates analysis of distribution of 243 
extraintestinal pathogenic Escherichia coli isolates from human 
feces and poultry products, Minnesota and Wisconsin, 2002–
2004, on the axis 1–axis 2 plane. Data include extended virulence 
genotypes (60 traits) and phylogenetic group (A, B1, B2, D). The 
axes have no units; they reﬂ  ect the total score for each isolate 
derived by summing the isolate’s partial score for each variable, 
which is the product of the loading score assigned to the particular 
variable for a given axis and the isolate’s status for that variable. 
Axis 1 (positive values to right, negative values to left of central 
vertical line) accounted for 37% of total variance and showed 
signiﬁ   cant differences between susceptible human isolates 
versus each of the other groups. Axis 2 (positive values above, 
negative values below central horizontal line) accounted for 20% 
of total variance and did not show any signiﬁ  cant between-group 
differences. Resistant, resistant to trimethoprim-sulfamethoxazole, 
nalidixic acid (quinolones), and ceftriaxone or ceftazidime 
(extended-spectrum cephalosporins). Susceptible, susceptible to 
all these agents (regardless of other possible drug resistance).
Figure 2. Distribution of virulence factor scores by source 
and resistance status among 243 extraintestinal pathogenic 
Escherichia coli isolates from human feces and poultry products, 
Minnesota and Wisconsin, 2002–2004. Resistant, resistant to 
trimethoprim-sulfamethoxazole, nalidixic acid (quinolones), and 
ceftriaxone or ceftazidime (extended-spectrum cephalosporins). 
Susceptible, susceptible to all these agents (regardless of other 
possible resistances). The virulence scores of the susceptible 
human isolates are an average of ≈4 points greater than those of 
the resistant human isolates or poultry isolates.RESEARCH
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susceptible, poultry-source E. coli by conversion to resis-
tance. This most plausibly would occur within the avian 
fecal ﬂ  ora under selection pressure from on-farm use of 
antimicrobial drugs.
Our ﬁ  ndings closely resemble those of a recent study 
of ciproﬂ  oxacin-resistant E. coli from humans and chick-
ens in the late 1990s in Barcelona, Spain (12). These data 
indicate that these relationships remain valid and are 
applicable in the United States, to additional resistance 
phenotypes (speciﬁ  cally quinolones, TMP-SMZ, and ex-
tended-spectrum cephalosporins), and to retail poultry 
products (12). Moreover, similar results were obtained 
with retail poultry products and poultry carcasses from 
processing plants. This implies that drug-resistant poul-
try-source E. coli isolates originate in the birds, rather 
than being introduced from some exogenous reservoir 
later during the packaging and distribution process. This 
in turn suggests that on-farm practices, including use of 
antimicrobial agents for growth promotion, metaphylaxis, 
and therapy (21,22), may inﬂ  uence characteristics of E. 
coli that contaminate retail poultry products and, seem-
ingly, are then transmitted to humans (7).
The greater overall similarity of drug-resistant human 
isolates to poultry isolates than to drug-susceptible human 
isolates applied not only to the hospital patient isolates com-
pared with isolates from conventionally raised poultry, but 
also to the isolates from vegetarians compared with isolates 
from poultry raised with no antibiotics. This was surprising 
because the vegetarians ostensibly did not consume poul-
try and, therefore, should not have been directly exposed 
to poultry-source E. coli. However, this seeming paradox 
is consistent with the difﬁ  culty in conﬁ  rming poultry con-
sumption (along with most other individual-level expo-
sures) as an epidemiologic risk factor for colonization with 
drug-resistant E. coli isolates among community-dwelling 
persons ([23]; J.R. Johnson, unpub. data). Assuming that 
the drug-resistant human isolates were derived from poul-
try, occurrence of poultry-source E. coli in both vegetarians 
and persons with conventional diets suggests that poul-
try-source drug-resistant E.  coli may spread extensively 
through the human population without requiring individual 
exposure to poultry products. This suggestion would be 
consistent with evidence that household-level risk factors 
may be more predictive of colonization with drug-resistant 
E. coli than individual-level risk factors, and that house-
hold members often share E. coli clones with each another 
(23–25). The mechanisms for such diffusion, and methods 
to block the entry of such strains into the human population 
and their subsequent spread, need to be deﬁ  ned.
The virulence potential for humans of the present 
drug-resistant human and poultry E. coli isolates, which is 
related to their direct threat to human health, is unknown. 
Predictions regarding virulence potential await molecular 
comparisons with human clinical isolates (9,10,12) and ex-
perimental virulence assessment in vivo (26,27). Nonethe-
less, the abundance of ExPEC-associated virulence genes 
in some of these strains is of concern because it suggests 
a high likelihood of virulence. This would augment any 
health threat these strains may pose as passive vehicles for 
drug-resistance genes (6,7).
Potential limitations of this study warrant comment. 
Because we did not examine alternative sources for drug-
resistant human isolates, we cannot exclude the possibility 
that other foods (28) or nonfood reservoirs (29) might yield 
even closer similarities to drug-resistant human isolates. 
Whether persons in the study consumed poultry products 
from the same lots or suppliers as those sampled is not 
known. Because the study was conducted in Minnesota 
and Wisconsin in mostly rural communities and with new-
ly hospitalized patients and nonhospitalized vegetarians, 
generalizability of the results is unknown. We combined 
several resistance phenotypes because of low frequencies, 
which may have obscured differences. We also did not as-
sess other molecular characteristics of strains, e.g., pulsed-
ﬁ  eld gel electrophoresis proﬁ  les (12), sequence types (30), 
Figure 3. Dendrogram based on extended virulence proﬁ  les of 243 
extraintestinal pathogenic Escherichia coli isolates from human 
feces and poultry products, Minnesota and Wisconsin, 2002–2004. 
The dendrogram (shown here in simpliﬁ  ed form) was constructed 
by using the unweighted pair group method with arithmetic 
averages based on pairwise similarity relationships according 
to the aggregate presence or absence of 60 individual virulence 
genes plus phylogenetic group (A, B1, B2, D). Triangles indicate 
arborizing subclusters. Major clusters 1, 2, and 3, and subclusters 
1a, 1b, 2a, 2b, 3a, and 3b are indicated. Colored boxes to right of 
dendrogram show the distribution (by source group) of constituent 
members of each subcluster. Resistant, resistant to trimethoprim-
sulfamethoxazole, nalidixic acid (quinolones), and ceftriaxone or 
ceftazidime (extended-spectrum cephalosporins). Susceptible, 
susceptible to all these agents.Drug-Resistant E. coli from Humans and Poultry
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and resistance elements (28). Use of multiple comparisons 
increased the likelihood of spurious associations (which 
we addressed by specifying a strict criterion for statistical 
signiﬁ  cance), whereas the small sample size in certain sub-
groups reduced power for ﬁ  nding true associations.
Strengths of the study include substantial overall 
sample size, standardized concurrent processing of fecal 
and poultry samples, close matching of human and poultry 
samples, extensive molecular typing using virulence-rel-
evant markers, and use of multiple analytical modalities. 
Additionally, we examined clinically relevant resistance 
phenotypes.
In summary, our ﬁ  ndings suggest that in a contempo-
rary US-based population, many human-source drug-resis-
tant fecal E. coli isolates more likely originated in poultry 
than in humans, whereas drug-resistant poultry isolates 
likely derive from drug-susceptible poultry isolates. Our 
data extend this paradigm to clinically relevant agents oth-
er than ﬂ  uoroquinolones, heighten concerns regarding the 
potential human health risk for antimicrobial drug use in 
poultry production, and suggest that avoidance of poultry 
consumption may not reliably provide personal protection.
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